Compare Dover Corp (DOV) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Twist Bioscience Corp — how do they compare? Dover Corp trades at $190.16 (market cap $25.45B), while Twist Bioscience Corp trades at $152.84 (market cap $10.08B). The key difference: Dover Corp is far larger — about 2.5× Twist Bioscience Corp's market cap, and Dover Corp pays a 1.11% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 73 Days and Twist Bioscience Corp for 27 Days on average.
| DOV | TWST | |
|---|---|---|
Market Cap | $25.45B | $10.08B |
Volume | 661,758 | 4,229,037 |
Sector | Industrials | Health |
52-Week High | $233.31 | $205.00 |
52-Week Low | $161.16 | $25.45 |
Typical Hold Time | 73 Days | 27 Days |
Enterprise Value | $26.95B | $10.01B |
Dividend Yield | 1.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $188.29, down 1.87% on the day, with a bearish technical signal from moving averages. The company maintains strong profitability with a 13.48% net income margin and has beaten earnings expectations for three consecutive quarters. Recent acquisitions and product launches demonstrate ongoing business development. Analyst consensus remains strongly bullish with a $243.20 price target representing 29% upside potential.
The stock offers attractive upside based on analyst targets and consistent earnings performance, though technical indicators suggest near-term pressure. Key risks include market volatility and integration challenges from recent acquisitions. The company's Dividend King status and strong cash flow generation provide stability for long-term investors.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
